BRAF and melanoma: Nine therapeutic drugs (including BRAF and MAPK/ERK kinase (MEK) inhibitors and cytotoxic T lymphocyte antigen 4 (CTLA4)‐ and PD1-directed mAbs) have been approved by the FDA for melanoma in the past three decades (Fig. 8a and Table 7).